Company Revenue

The company grew in the mid-teens and could see even greater demand with MACI Arthro's use for trochlea defects....

The company's orthopedic sales declined about 10% in the first quarter of 2025, but its commercial channel showed ample promise....

The company grew in the low single digits for the first quarter of 2025 and expects accelerating growth through the...

The company faced market softness, supply issues and international order timing lumpiness as it declined in the low single digits....

The company's orthopedic sales grew 6% in the first quarter of 2025 on the strength of DUROLANE and Exogen....

The company grew nearly 25% in the first quarter of 2025 as its physician user base reached record levels....

The company grew in the low single digits for 1Q25 due to one less selling day and distributor team transitions....

The company grew in the low single digits in the first quarter of 2025 and it retools its U.S. sales...

The company grew more than 20% in the first quarter of 2025 as it seeks to cement itself as the...

The company maintained its exceptional pace of orthopedic growth during the first quarter of 2025 driven by execution and robotic...